Insightec Announces Registration Approval Of Exablate Neuro By Singapore Health Sciences Authority
News provided by
Share this article
Share this article
Positive momentum continues to bring Focused Ultrasound to global patients living with Essential Tremor and Tremor-dominant Parkinson s Disease
HAIFA, Israel and MIAMI, July 5, 2021 /PRNewswire/ Insightec®, a global healthcare company focused on creating the next generation of patient care, announced approval of the Exablate® Neuro platform by the Health Sciences Authority (HSA) in Singapore.
The Exablate Neuro (Exablate 4000) platform uses Focused Ultrasound to ablate a target deep in the brain. The unilateral treatment is suitable for patients with Essential Tremor (age 22 or older) or Tremor-dominant Parkinson s Disease (age 30 or older) who have not responded to medications.